#London #United Kingdom #Virax Biolabs #Long COVID #ViraxImmune

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™

In a significant stride for patients suffering from Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and related post-acute infection syndromes (PAIS), Virax Biolabs Group Limited (NASDAQ: VRAX) has recently disclosed encouraging results from the early pilot data for its innovative blood-based test, ViraxImmune™. The findings highlight the test's potential to objectively assess immune responses, a development that could revolutionize current diagnostic practices in this challenging and often misunderstood area of health.

Encouraging Results from Initial Trials

The pilot study revealed that ViraxImmune™ successfully distinguished between patients affected by PAIS and healthy individuals, achieving impressive metrics of 88% specificity and 92% positive predictive value (PPV). These figures suggest a strong capability of the test to accurately identify conditions associated with Long COVID and ME/CFS, a feat that traditional diagnostic methods often struggle to accomplish.

Virax has noted that their test has already been evaluated among more than 120 subjects in an ongoing clinical study in the UK. This initial dataset serves not simply as evidence of the test’s efficacy but also as a foundation for future studies and potential regulatory approval, particularly in the United States where estimates suggest up to 21 million adults may be living with Long COVID and PAIS. Additionally, there are around 2.5 million new cases anticipated annually, indicating a crucial and expanding need for effective diagnostic tools in this domain.

Future Development Plans

Building on the momentum of these initial results, Virax is preparing for the next critical phase of their research strategy, which includes a broader clinical validation analysis that will involve previously collected samples from an additional 300 participants. This data analysis is set to commence in the fourth quarter of 2026, with results expected in early 2027, and will indeed be pivotal in establishing the test’s reliability and efficacy.

The remarks from James Foster, Chairman and CEO of Virax Biolabs, underscore the significance of this progress, stating, "These early pilot data mark an important step in the development of ViraxImmune™ as a potential objective immune-profiling test. The observed separation between patients and healthy controls, together with encouraging early performance metrics, supports our confidence that ViraxImmune™ has a major role to play in addressing a critical diagnostic need."

In line with this, Dr. Sean Knight, a principal investigator at the University of Manchester, pointed out the burdens faced by patients who often endure lengthy diagnostic pathways and the insufficiency of objective testing options. He expressed optimism about the potential of immune profiling in enhancing diagnosis, ensuring that patients have timely and accurate assessments of their health conditions.

Implications for Patients and Future Healthcare

The advent of ViraxImmune™ could herald a new era of diagnostics, offering a more reliable method for patient stratification, clinical decision-making, and monitoring over time. Given the complex nature of Long COVID and related syndromes, this test aims to integrate objective analysis into patient care, a significant shift from the current reliance on symptomatic evaluations and exclusion criteria.

As Virax tests progress, stakeholders, including healthcare professionals and patients, are closely monitoring developments. An investor webcast is scheduled for May 26, 2026, to delve into the early data findings and outline future directions, amplifying the company’s commitment to transparency and informed growth.

ViraxImmune™ remains under development and is not yet approved for diagnostic use in any jurisdiction. These early observations are foundational, intended to shape ongoing assay development and subsequent clinical validation. The broader implications for this test could extend not only to improved diagnostic strategies for Long COVID and related conditions but also potentially influence therapeutic development, streamlining pathways towards improved patient outcomes.

In summary, as Virax Biolabs continues to advance its research, the medical community and patients alike remain hopeful that the emergence of objective testing through ViraxImmune™ will dramatically enhance the understanding and management of Long COVID and related syndromes.